nach oben

Erschienen in:

09.01.2022 | Review Article

Controversies and Challenges in the Management of Osteosarcoma—an Indian Perspective

verfasst von: Abhenil Mittal, Deepam Pushpam, Shuvadeep Ganguly, Venkatesan Sampath Kumar, Shah Alam Khan, Sameer Bakhshi

Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Osteosarcoma (OGS) is the most common primary bone tumor in children and adolescents which requires a multidisciplinary approach to management. Although chemotherapy and surgery can cure more than half of localized OGS cases, the unique challenges faced by resource-limited countries like India make this outcome difficult to achieve. Various questions in the management of OGS including role of high-dose methotrexate (HDMTX) in neoadjuvant setting, triplet vs doublet chemotherapy, intensification of chemotherapy based on response in setting of doublet, and indigenous prosthesis in setting of limb salvage need to be defined. Similarly, in the metastatic and recurrent setting, questions regarding intent of treatment, indications of chemotherapy, timing of surgery, and role of targeted therapies need clarification. Lack of randomized trials from India makes definite conclusions difficult, but an attempt can be made to define the best approach in the Indian scenario from available evidence. Hence, a critical review of literature from India and the West was done to define possible management approaches and highlight the lacuna for future research.

Link MP, Eilber F (1989) Paediatric oncology: OS. In: Pizzo PA, Poplack DG (eds) Principles and practice of paediatric oncology. Lippincott, Philadelphia, PA

CADE S. Osteogenic sarcoma; a study based on 133 patients. J R Coll Surg Edinb 1955 Dec;1(2):79-111

Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB et al (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with OS of the extremity. N Engl J Med 314(25):1600–1606CrossRef

Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A et al (1991) Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res 270:8–14CrossRef

Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML et al (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23(9):2004–2011CrossRef

Ramaswamy A, Rekhi B, Bakhshi S, Hingmire S, Agarwal M (2016) Indian data on bone and soft tissue sarcomas: a summary of published study results. South Asian J Cancer 5(3):138–145CrossRef

Swaminathan R, Rama R, Shanta V (2008) Childhood cancers in Chennai, India, 1990-2001: incidence and survival. Int J Cancer 122(11):2607–2611CrossRef

Jain K, Sunila RR, Mruthyunjaya RCS, Gadiyar HB et al (2011) Bone tumors in a tertiary care hospital of south India: a review 117 cases. Indian J Med Paediatr. Oncol. 32(2):82–85. https://doi.org/10.4103/0971-5851.89778CrossRef

Gulia A, Puri A, Chorge S, Panda PK (2016) Epidemiological data and case load spectrum of patients presenting to bone and soft tissue disease management group at a tertiary cancer center. Indian J Cancer 53(2):333–338CrossRef

10.

Sharma N, Ahmad A, Bhat GM, Aziz SA, Lone MM, Bhat NA (2017) A profile of pediatric solid tumors: a single institution experience in Kashmir. Indian J Med Paediatr Oncol 38(4):471CrossRef

11.

Singh R, Shirali R, Chatterjee S, Adhana A, Arora RS (2016) Epidemiology of cancers among adolescents and young adults from a tertiary cancer center in Delhi. Indian J Med Paediatr Oncol 37(2):90–94CrossRef

12.

Kakkar N, Gupta A, Sharma NK, Agarwal P, Kaur J (2017) Adolescents and young adults: a study of distribution of cancer at ages 15-39 years in a tertiary care hospital from North India: Epidemiological considerations. South Asian J Cancer 6(4):180–182CrossRef

13.

Pandey A, Singh A, Kumar V, Prakash J, Runu R, Thakur V et al (2020) Pediatric cancers in Bihar: a retrospective tertiary cancer center study. South Asian J Cancer 9(1):53CrossRef

14.

http://ncdirindia.org/NCRP/ALL_NCRP_REPORTS/PBCR_REPORT_2012_2014/index.htm

15.

http://seer.cancer.gov/publications/childhood/introduction.pdf (Accessed on May 31, 2011).

16.

Mirabello L, Troisi RJ, Savage SA (2009) OS incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 115(7):1531–1543CrossRef

17.

Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR (eds). Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. Bethesda, MD, 1999.

18.

Nataraj V, Batra A, Rastogi S, Khan SA, Sharma MC, Vishnubhatla S et al (2015) Developing a prognostic model for patients with localized OS treated with uniform chemotherapy protocol without high dose methotrexate: a single center experience of 237 patients. J Surg Oncol 112:662–668CrossRef

19.

Thorpe WP, Reilly JJ, Rosenberg SA (1979) Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy. Cancer. 43(6):2178–2181CrossRef

20.

Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A et al (1991) Adjuvant chemotherapy of high-grade OS of the extremity. Updated results of the Multi-Institutional OS Study. Clin Orthop Relat Res 270:8–14CrossRef

21.

Bakhshi S, Radhakrishnan V (2010) Prognostic markers in OS. Expert Rev Anticancer Ther 10:271–287CrossRef

22.

Puri A, Byregowda S, Gulia A, Crasto S, Chinaswamy G (2018) A study of 853 high grade OSs from a single institution-are outcomes in Indian patients different? J Surg Oncol 117(2):299–306CrossRef

23.

Poudel RR, Tiwari V, Kumar VS, Bakhshi S, Gamanagatti S, Khan SA et al (2017) Factors associated with local recurrence in operated OSs: a retrospective evaluation of 95 cases from a tertiary care center in a resource challenged environment. J Surg Oncol 115(5):631–636CrossRef

24.

Bajpai J, Puri A, Shah K, Susan D, Jambhekar N, Rekhi B et al (2013) Chemotherapy compliance in patients with OS. Pediatr Blood Cancer 60(1):41–44CrossRef

25.

Rastogi S, Kumar R, Sankineani SR, Marimuthu K, Rijal L, Prakash S et al (2012) Role of vascular endothelial growth factor as a tumour marker in OS: a prospective study. Int Orthop 36(11):2315–2321CrossRef

26.

Bajpai J, Kumar R, Sreenivas V, Sharma MC, Khan SA, Rastogi S et al (2011) Prediction of chemotherapy response by PET-CT in OS: correlation with histologic necrosis. J Pediatr Hematol Oncol 33(7):e271–e278CrossRef

27.

Bajpai J, Gamnagatti S, Kumar R, Sreenivas V, Sharma MC, Khan SA et al (2011) Role of MRI in OS for evaluation and prediction of chemotherapy response: correlation with histological necrosis. Pediatr Radiol 41(4):441–450CrossRef

28.

Bajpai J, Sharma M, Sreenivas V, Kumar R, Gamnagatti S, Khan SA et al (2009) VEGF expression as a prognostic marker in OS. Pediatr Blood Cancer 53(6):1035–1039CrossRef

29.

Bakhshi S, Gupta A, Sharma MC, Khan SA, Rastogi S (2009) Her-2/neu, p-53, and their coexpression in OS. J Pediatr Hematol Oncol 31(4):245–251CrossRef

30.

Rakesh Kumar V, Gupta N, Kakkar N, Sharma SC (2006) Prognostic and predictive value of c-erbB2 overexpression in osteogenic sarcoma. J Cancer Res Ther 2(1):20–23. https://doi.org/10.4103/0973-1482.19770CrossRef

31.

Nataraj V, Rastogi S, Khan SA, Sharma MC, Agarwala S, Vishnubhatla S et al (2016) Prognosticating metastatic OS treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: a single center experience of 102 patients. Clin Transl Oncol 18(9):937–944CrossRef

32.

Bielack SS, Kempf-Bielack B, Delling G, Exner UG, Flege S, Helmke K et al (2002) Prognostic factors in high-grade OS of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative OS study group protocols. J Clin Oncol 20(3):776–790CrossRef

33.

Hauben EI, Weeden S, Pringle J, Van Marck EA, Hogendoorn PC (2002) Does the histological subtype of high-grade central OS influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European OS Intergroup. Eur J Cancer 38(9):1218–1225CrossRef

34.

Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P (2006) Prognostic factors for OS of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106(5):1154–1161. https://doi.org/10.1002/cncr.21724CrossRef

35.

Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC et al (2011) Chemotherapeutic adjuvant treatment for OS: where do we stand? Eur J Cancer 47(16):2431–2445CrossRef

36.

Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB et al (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic OS: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21(8):1574–1580CrossRef

37.

Rosen G, Caparros B, Huvos AG et al (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49(6):1221–1230CrossRef

38.

Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG et al (1998) Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 16(7):2452–2458CrossRef

39.

Bacci G, Picci P, Pignatti G, De Cristofaro R, Dallari D, Avella M et al (1991) Neoadjuvant chemotherapy for nonmetastatic OS of the extremities. Clin Orthop Relat Res 270:87–89CrossRef

40.

Souhami RL, Craft AW, Eijken JW, Nooji M, Spooner D, Bramwell VH et al (1997) Randomised trial of two regimens of chemotherapy in operable OS: a study of the European OS Intergroup. Lancet 350:911–917CrossRef

41.

Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC et al (2007) Improvement in histologic response but not survival in OS patients treated with intensified chemotherapy: a randomized phase III trial of the European OS Intergroup. J Natl Cancer Inst 99(2):112–128CrossRef

42.

Fuchs N, Bielack SS, Epler D, Beiling P, Delling G, Korholz D et al (1998) Long-term results of the co-operative German-Austrian-Swiss OS study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for OS of the limbs. Ann Oncol 9(8):893–899CrossRef

43.

Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML et al (2005) OS: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23(9):2004–2011CrossRef

44.

Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Kralio MD et al (2016) Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade OS (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol 17(10):1396–1408CrossRef

45.

Bajpai J, Chandrasekharan A, Simha V, Mandal T, Shah K, Hingmare S et al (2019) OS journey over two decades in India: small steps, big changes. Pediatr Blood Cancer 66(9):e27877CrossRef

46.

Sukumaran RK, Rajeshwari B, Sugath S, Chellappan SG, Thankamony P, Parukuttyamma K (2018) Methotrexate free chemotherapy and limb salvage surgery for paediatric OS in India. Indian J Orthop 52(1):58–64CrossRef

47.

Shanmugam S, Govindasamy G, Hussain SA, Fells SPS (2019) Pediatric bone sarcomas: outcome of multimodality treatment in a single institution in South India over a decade. Indian J Med Paediat Oncol 40(5):38

48.

Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfürst C et al (1988) Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6(2):329–337CrossRef

49.

Bramwell VH, Burgers M, Sneath R et al (1992) A comparison of two short intensive adjuvant chemotherapy regimens in operable OS of limbs in children and young adults: the first study of the European OS Intergroup. J Clin Oncol 10:1579–1591CrossRef

50.

van Dalen EC, van As JW, de Camargo B (2011) Methotrexate for high-grade OS in children and young adults. Cochrane Database Syst Rev 5:CD006325

51.

Patel SJ, Lynch JW Jr, Johnson T, Caroli RR, Schumacher C, Spanier S et al (2002) Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for OS in adults. Am J Clin Oncol 25:489–495CrossRef

52.

Piperno-Neumann S, Bui B, Blay J et al (2006) A multicentric prospective study of intensive induction chemotherapy (APIAI) in localized OS patients: results of a phase II trial coordinated by the French Sarcoma Group (FSG) and the FNCLCC BECT. J Clin Oncol 24:9521CrossRef

53.

Tunn PU, Reichardt P (2007) Chemotherapy for OS without high-dose methotrexate: a 12-year follow-up on 53 patients. Onkologie 30:228–232

54.

Assi H, Missenard G, Terrier P, Le Pechoux C, Bonvalot S, Vanel D et al (2010) Intensive induction chemotherapy without methotrexate in adult patients with localized OS: results of the Institut Gustave-Roussy phase II trial. Curr Oncol 17:23–31CrossRef

55.

Daw NC, Neel MD, Rao BN, Billups CA, Wu J, Jenkins JJ et al (2011) Frontline treatment of localized OS without methotrexate: results of the St. Jude Children’s Research Hospital OS99 trial. Cancer 117:2770–2778CrossRef

56.

Bajpai J, Chandrasekharan A, Talreja V, Simha V, Chandrakanth MV, Rekhi B et al (2017) Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'. Eur J Cancer 85:49–58CrossRef

57.

Craft AW (2009) OS: the European OS Intergroup (EOI) perspective. Cancer Treat Res 152:263–274CrossRef

58.

Poudel RR, Kumar VS, Bakhshi S, Gamanagatti S, Rastogi S, Khan SA (2014) High tumor volume and local recurrence following surgery in OS: a retrospective study. Indian J Orthop 48(3):285CrossRef

59.

Li X, Zhang Y, Wan S et al (2016) A comparative study between limb-salvage and amputation for treating OS. J Bone Oncol 5(1):15–21. https://doi.org/10.1016/j.jbo.2016.01.001CrossRef

60.

Grimer RJ, Taminiau AM, Cannon SR (2002) Surgical subcommitte of the European Osteosarcoma Intergroup. Surgical outcomes in osteosarcoma. J Bone Joint Surg (Br) 84:395–400CrossRef

61.

Bispo Júnior RZ, Camargo OP de. Prognostic factors in the survival of patients diagnosed with primary non-metastatic osteosarcoma with a poor response to neoadjuvant chemotherapy. Clin São Paulo Braz 2009;64:1177–1186.

62.

Khan SA, Kumar VS, Poudel RR Limb salvage in India. In Sarcoma 2017 (pp. 483-510). Springer. Cham.

63.

Puri A (2014) Orthopedic oncology - "the challenges ahead". Front Surg 1:27. https://doi.org/10.3389/fsurg.2014.00027CrossRef

64.

Tiwari A, Mehta S, Sharma SK, Chauhan V, Rohela H, Arora R (2019) Vascularized fibula with and without extracorporeal radiotherapy for limb salvage surgery in Indian patients. J Clin Orthop Trauma 10(1):167–172CrossRef

65.

Puri A, Byregowda S, Gulia A, Patil V, Crasto S, Laskar S (2018) Reconstructing diaphyseal tumors using radiated (50 Gy) autogenous tumor bone graft. J Surg Oncol 118(1):138–143CrossRef

66.

Nayak P, Gulia A, Puri A. Does reconstruction with reimplantation of sterilized tumor bone provide survival benefit in diaphyseal OS? [Internet]. Vol. 2020, Sarcoma. Hindawi; 2020 [cited 2020 Aug 31]. p. e4092790

67.

Natarajan MV, Sivaseelam A, Rajkumar G, Hussain SHJ (2003) Custom megaprosthetic replacement for proximal tibial tumours. Int Orthop 27(6):334–337CrossRef

68.

Natarajan MV, Sivaseelam A, Ayyappan S, Bose JC, Sampath KM (2005) Distal femoral tumours treated by resection and custom mega-prosthetic replacement. Int Orthop 29(5):309–313CrossRef

69.

Agarwal M, Anchan C, Shah M, Puri A, Pai S (2007) Limb salvage surgery for OS: effective low-cost treatment. Clin Orthop Relat Res 459:82–91CrossRef

70.

Chauhan A, Joshi GR, Chopra BK, Ganguly M, Reddy GR (2013) Limb salvage surgery in bone tumors: a retrospective study of 50 cases in a single center. Indian J Surg Oncol 4(3):248–254CrossRef

71.

Tiwari A, Jain S, Mehta S, Kumar R, Kapoor G, Kumar K (2014) Limb salvage surgery for OS: early results in Indian patients. Indian J Orthop 48(3):266–272CrossRef

72.

Hong AM, Millington S, Ahern V, McCowage G, Boyle R, Tattersall M et al (2013) Limb preservation surgery with extracorporeal irradiation in the management of malignant bone tumor: the oncological outcomes of 101 patients. Ann Oncol 24(10):2676–2680CrossRef

73.

Pruksakorn D, Kongthavonskul J, Teeyakasem P, Phanphaisarn A, Chaiyawat P, Klangjorhor J et al (2018) Surgical outcomes of extracorporeal irradiation and re-implantation in extremities for high grade osteosarcoma: a retrospective cohort study and a systematic review of the literature. J Bone Oncol 14:100210CrossRef

74.

Sharma DN, Rastogi S, Bakhshi S, Rath GK, Julka PK, Laviraj MA et al (2013) Role of extracorporeal irradiation in malignant bone tumors. Indian J Cancer 50(4):306CrossRef

75.

Chauhan S, Khan SA, Prasad A (2018) Irradiation-induced compositional effects on human bone after extracorporeal therapy for bone sarcoma. Calcif Tissue Int 103(2):175–188CrossRef

76.

Xu M, Xu M, Zhang S, Li H, Qiuchi AI, Yu X et al (2021) Comparative efficacy of intraoperative extracorporeal irradiated and alcohol-inactivated autograft reimplantation for the management of osteosarcomas-a multicentre retrospective study. World J Surg Oncol 19(1):157CrossRef

77.

Bernthal NM, Monument MJ, Randall RL, Jones KB (2014) Rotationplasty: beauty is in the Eye of the Beholder. Oper Tech Orthop 24(2):103–110CrossRef

78.

Winkelmann WW (2000) Type-B-IIIa hip rotationplasty: an alternative operation for the treatment of malignant tumors of the femur in early childhood. J Bone Joint Surg Am 82:814–828CrossRef

79.

Agarwal M, Puri A, Anchan C, Shah M, Jambhekar N (2007) Rotationplasty for bone tumors: is there still a role? Clin Orthop Relat Res 459:76–81. https://doi.org/10.1097/BLO.0b013e31805470f0CrossRef

80.

Heisel C, Kinkel S, Bernd L, Ewerbeck V (2006) Megaprostheses for the treatment of malignant bone tumours of the lower limbs. Int Orthop 30:452–457CrossRef

81.

Ahlmann ER, Menendez LR, Kermani C, Gotha H (2006) Survivorship and clinical outcome of modular endoprosthetic reconstruction for neoplastic disease of the lower limb. J Bone Joint Surg (Br) 88:790–795CrossRef

82.

Machak GN, Tkachev SI, Solovyev YN, Sinyukov PA, Ivanov SM, Kochergina NV et al (2003) Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin Proc 78(2):147–155CrossRef

83.

Caceres E, Zaharia M, Valdivia S, Misad O, de la Flor J, Tejada F et al (1984) Local control of osteogenic sarcoma by radiation and chemotherapy. Int J Radiat Oncol Biol Phys 10(1):35–39CrossRef

84.

Ciernik IF, Niemierko A, Harmon DC, Kobayashi W, Chen YL, Yock TI et al (2011) Proton-based radiotherapy for unresectable or incompletely resected OS. Cancer. 117(19):4522–4530CrossRef

85.

Salunke AA, Shah J, Warikoo V, Chakraborty A, Sahijwani H, Sharma M et al (2017) Surgical management of pelvic bone sarcoma with internal hemipelvectomy: oncologic and functional outcomes. J Clin Orthop Trauma 8(3):249–253. https://doi.org/10.1016/j.jcot.2017.04.004CrossRef

86.

Puri A, Pruthi M, Gulia A (2014) Outcomes after limb sparing resection in primary malignant pelvic tumors. Eur J Surg Oncol 40(1):27–33. https://doi.org/10.1016/j.ejso.2013.10.017CrossRef

87.

DeLaney TF, Park L, Goldberg SI, Hug EB, Liebsch NJ, Munzenrider JE et al (2005) Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys 61(2):492–498CrossRef

88.

Guadagnolo BA, Zagars GK, Raymond AK, Benjamin RS, Sturgis EM (2009) Osteosarcoma of the jaw/craniofacial region: outcomes after multimodality treatment. Cancer. 115(14):3262–3270CrossRef

89.

Laskar S, Basu A, Muckaden MA, D'Cruz A, Pai S, Jambhekar N et al (2008) Osteosarcoma of the head and neck region: lessons learned from a single-institution experience of 50 patients. Head Neck 30(8):1020–1026CrossRef

90.

Bacci G, Rocca M, Salone M, Balladelli A, Ferrari S, Palmerini E et al (2008) High grade OS of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol 98(6):415–420CrossRef

91.

Bacci G, Ferrari S, Longhi A, Perin S, Forni C, Fabbri N et al (2001) Pattern of relapse in patients with OS of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer 37(1):32–38CrossRef

92.

Bajpai J, Chandrasekharan A, Simha V, Talreja V, Karpe A, Pandey N et al (2018) Outcomes in treatment-naïve patients with metastatic extremity OS treated with OGS-12, a novel non-high-dose methotrexate-based, dose-dense combination chemotherapy, in a tertiary care cancer center. J Glob Oncol 4:1–10

93.

Kager L, Zoubek A, Pötschger U, Flege S, Kempf-Bielack B, Branscheid D et al (2003) Primary metastatic OS: presentation and outcome of patients treated on neoadjuvant Cooperative OS Study Group protocols. J Clin Oncol 21:2011–2018CrossRef

94.

Ferguson WS, Harris MB, Goorin AM, Gebhardt MC, Link MP, Shochat SJ et al (2001) Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable OS: Pediatric Oncology Group trial. J Pediatr Hematol Oncol 23:340–348CrossRef

95.

Pramanik R, Agarwala S, Gupta YK, Thulkar S, Vishnubhatla S, Batra A et al (2017) Metronomic chemotherapy vs best supportive care in progressive pediatric solid malignant tumors: a randomized clinical trial. JAMA Oncol 3(9):1222–1227CrossRef

96.

Petrella F, Diotti C, Rimessi A, Spaggiari L (2017) Pulmonary metastasectomy: an overview. J Thorac Dis 9(Suppl 12):S1291–S1298CrossRef

97.

Kempf-Bielack B, Bielack SS, Jürgens H, Branscheid D, Berdel WE, Exner GU et al (2005) Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23:559–568CrossRef

98.

Harting MT, Blakely ML, Jaffe N, Cox C Jr, Hayes-Jordan A, Benjamin RS et al (2006) Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg 41:194–199CrossRef

99.

Letourneau PA, Xiao L, Harting MT, Lally KP, Cox C Jr, Andrassy RJ et al (2011) Location of pulmonary metastasis in pediatric osteosarcoma is predictive of outcome. J Pediatr Surg 46:1333–1337CrossRef

100.

Leary SE, Wozniak AW, Billups CA, Wu J, McPhearson V, Neel MD et al (2013) Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children’s Research Hospital experience. Cancer 119:2645–2653CrossRef

101.

Briccoli A, Rocca M, Salone M, Guzzardella GA, Balladelli A, Bacci G (2010) High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985-2005. Surg Oncol 19(4):193–199CrossRef

102.

Ramanujan V, Krishnamurthy A, Venkataramani K, Kumar C (2020) Pulmonary metastasectomy in primary extremity OS: choosing wisely, along with a brief review of literature. Indian J Cancer 57(2):172–181

103.

Putnam JB Jr, Roth JA, Wesley MN, Johnston MR, Rosenberg SA (1983) Survival following aggressive resection of pulmonary metastases from osteogenic sarcoma: analysis of prognostic factors. Ann Thorac Surg 36(5):516–523CrossRef

104.

Goorin AM, Delorey MJ, Lack EE, Gelber RD, Price K, Cassady JR et al (1984) Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients. J Clin Oncol 2(5):425–431CrossRef

105.

Ferrari S, Briccoli A, Mercuri M, Bertoni F, Picci P, Tienghi A et al (2003) Post relapse survival in OS of the extremities: prognostic factors for long-term survival. J Clin Oncol 21:710–715CrossRef

106.

Bielack SS, Kempf-Bielack B, Branscheid D, Carrie D, Friedel G, Helmke K et al (2009) Second and subsequent recurrences of OS: presentation, treatment, and outcomes of 249 consecutive cooperative OS study group patients. J Clin Oncol 27(4):557–565CrossRef

107.

Chou AJ, Merola PR, Wexler LH, Gorlick RG, Vyas YM, Healey JH et al (2005) Treatment of OS at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer. 104(10):2214–2221CrossRef

108.

Berrak SG, Pearson M, Berberoğlu S, Ilhan IE, Jaffe N (2005) High-dose ifosfamide in relapsed pediatric OS: therapeutic effects and renal toxicity. Pediatr Blood Cancer 44(3):215–219CrossRef

109.

Palmerini E, Jones RL, Marchesi E, Paioli A, Cesari M, Longhi A et al (2016) Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. BMC Cancer 20(16):280CrossRef

110.

Rodríguez-Galindo C, Daw NC, Kaste SC, Meyer WH, Dome JS, Pappo AS et al (2002) Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. J Pediatr Hematol Oncol 24(4):250–255CrossRef

111.

Fox E, Patel S, Wathen JK, Schuetze S, Chawla S, Harmon D et al (2012) Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist. 17(3):321CrossRef

112.

Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Forquer R et al (1987 Aug) Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 5(8):1191–1198CrossRef

113.

Cairo MS, Shen V, Krailo MD, Bauer M, Miser JS, Sato JK et al (2001) Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report. J Pediatr Hematol Oncol 23(1):30–38CrossRef

114.

Nathan SS, Gorlick R, Bukata S, Chou A, Morris CD, Boland PJ et al (2006) Treatment algorithm for locally recurrent OS based on local disease-free interval and the presence of lung metastasis. Cancer. 107(7):1607–1616CrossRef

115.

Picci P, Sangiorgi L, Rougraff BT, Neff JR, Casadei R, Campanacci M (1994) Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in OS. J Clin Oncol 12(12):2699–2705CrossRef

116.

Rodriguez-Galindo C, Shah N, McCarville MB, Billups CA, Neel MN, Rao BN et al (2004) Outcome after local recurrence of OS: the St. Jude Children’s Research Hospital experience (1970–2000). Cancer. 100:1928–1935CrossRef

117.

Aung L, Gorlick R, Healey JH, Shi W, Thaler HT, Shorter NA et al (2003) Metachronous skeletal OS in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic OS. J Clin Oncol 21(2):342–348CrossRef

118.

Ozaki T, Flege S, Kevric M, Linder N, Maas R, Delling G et al (2003) OS of the pelvis: experience of the Cooperative OS Study Group. J Clin Oncol 21(2):334–341CrossRef

119.

Grignani G, Palmerini E, Pet D, Asaftei SD, D’Ambrosio L, Pignochino Y et al (2012) A phase II trial of sorafenib in relapsed and unresectable high-grade OS after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 23(2):508–516CrossRef

120.

Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S et al (2019) Randomized double-blind phase II study of regorafenib in patients with metastatic OS. J Clin Oncol 37(16):1424–1431CrossRef

121.

Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E et al (2019 Jan) French Sarcoma Group. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 20(1):120–133CrossRef

122.

Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2020 Mar;21(3):446-455

123.

Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D et al (2008) Children's Oncology Group. OS: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol 26(4):633–638CrossRef

124.

Chou AJ, Kleinerman ES, Krailo MD, Chen Z, Betcher DL, Healey JH et al (2009) Children's Oncology Group. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic OS: a report from the Children's Oncology Group. Cancer. 115(22):5339–5348CrossRef

125.

Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J et al (2017) Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18(11):1493–1501CrossRef

126.

Pincez T, Clément N, Lapouble E, Pierron G, Kamal M, Bieche I et al (2017) Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors. Pediatr Blood Cancer 64(6)

127.

Weidenbusch B, Richter GHS, Kesper MS, Guggemoos M, Gall K, Prexler C et al (2018) Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy. Oncotarget. 9(29):20747–20760CrossRef

128.

Suehara Y, Alex D, Bowman A, Middha S, Zehir A, Chakravarty D et al (2019) Clinical genomic sequencing of pediatric and adult osteosarcoma reveals distinct molecular subsets with potentially targetable alterations. Clin Cancer Res 25(21):6346–6356CrossRef

Titel: Controversies and Challenges in the Management of Osteosarcoma—an Indian Perspective
verfasst von: Abhenil Mittal
Deepam Pushpam
Shuvadeep Ganguly
Venkatesan Sampath Kumar
Shah Alam Khan
Sameer Bakhshi
Publikationsdatum: 09.01.2022
Verlag: Springer India
Erschienen in: Indian Journal of Surgical Oncology / Ausgabe 4/2022
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI: https://doi.org/10.1007/s13193-021-01486-3

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich

weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

Imaging Features of Breast Cancer Subtypes on Mammography and Ultrasonography: an Analysis of 479 Patients

Whole Breast Reconstruction in Developing India: a Cancer Surgeon’s Experience with the Pedicled Transverse Rectus Abdominis (TRAM) Flap

Mitigating Cancer Overdiagnosis

Utility of Scrape Cytology in Management of Ovarian Neoplasms: a Cross-sectional Study in a Tertiary Care Hospital of Eastern India

Gastric Gastro-intestinal Stromal Tumour Presenting as an Acute Perforation Peritonitis in a Young Male

Survival and Quality of Life (QoL) Enhancing Effect of Surgery in Larynx and Hypopharynx Cancers

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Hinter dieser Appendizitis steckte ein Erreger

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Ureterstriktur: Innovative OP-Technik bewährt sich

Update Chirurgie

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

S2e-Leitlinie „Distale Radiusfraktur“

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“